- TRL
- 3
Abstract
Researchers at Purdue University have designed molecules to concurrently inhibit two proteins important in tumorigenesis, MNK1/2 and p706SK. Pharmaceutical companies have pursued MNK1/2 and p706SK as individual targets; however, drugs targeting these proteins performed poorly as monotherapies. By inhibiting both MNK1/2 and p706SK with a single molecule, the Purdue researchers’ orally bioavailable compounds potently inhibit several solid tumor cancer cell lines, including breast, ovarian, lung, and colon cancer cells. Technology Validation: At 200 nM, one of the drugs designed by the researchers completely inhibited the growth of Caki-1 (renal cancer) and MDA-MB-231 (breast cancer) cells. Compounds were tested against the NCI-60 cell line panel. Advantages – Targets two oncogenic proteins with a single molecule – Effective against multiple solid tumor cell lines – Orally bioavailable Applications – Anticancer drugs
Website
https://prf.flintbox.com/technologies/49F9A790D0594634BA9F47DC69171589
Advantages
-Targets two oncogenic proteins with a single molecule
– Effective against multiple solid tumor cell lines
– Orally bioavailable
Potential Applications
-Anticancer drugs
Contact Information
Name: Joseph R Kasper
Email: JRKasper@prf.org
Phone: 765-588-3475